Q32 Bio Inc. (QTTB) stock
QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.53−0.10 (-1.16%)
Close on Nov 18, 2026Market cap $253.93MP/E –Yield –
Q32 Bio cash
Cash and short-term investments held at the end of each period.
Q32 Bio's cash was $106.27M at Jun 30, 2026. For fiscal 2025 it was $48.30M, down 38.6% from the year before. The highest annual figure on record is $262.39M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.30M | -38.6% |
| FY2024 | Dec 31, 2024 | $78.61M | +151.4% |
| FY2023 | Dec 31, 2023 | $31.26M | -83.6% |
| FY2022 | Dec 31, 2022 | $190.58M | +22.3% |
| FY2021 | Dec 31, 2021 | $155.87M | -28.3% |
| FY2020 | Dec 31, 2020 | $217.43M | -17.1% |
| FY2019 | Dec 31, 2019 | $262.39M | +22.2% |
| FY2018 | Dec 31, 2018 | $214.74M | +65.6% |
| FY2017 | Dec 31, 2017 | $129.66M | +1038.2% |
| FY2016 | Dec 31, 2016 | $11.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $106.27M | +93.8% |
| Q1 FY2026 | Mar 31, 2026 | $50.75M | -22.5% |
| Q4 FY2025 | Dec 31, 2025 | $48.30M | -38.6% |
| Q3 FY2025 | Sep 30, 2025 | $49.04M | -44.9% |
| Q2 FY2025 | Jun 30, 2025 | $54.83M | -49.1% |
| Q1 FY2025 | Mar 31, 2025 | $65.48M | -51.6% |
| Q4 FY2024 | Dec 31, 2024 | $78.61M | +151.4% |
| Q3 FY2024 | Sep 30, 2024 | $89.08M | -19.3% |
| Q2 FY2024 | Jun 30, 2024 | $107.65M | +53.1% |
| Q1 FY2024 | Mar 31, 2024 | $135.31M | -4.7% |
| Q4 FY2023 | Dec 31, 2023 | $31.26M | -83.6% |
| Q3 FY2023 | Sep 30, 2023 | $110.44M | -45.1% |
| Q2 FY2023 | Jun 30, 2023 | $70.33M | -68.8% |
| Q1 FY2023 | Mar 31, 2023 | $141.98M | -44.6% |
| Q4 FY2022 | Dec 31, 2022 | $190.58M | +22.3% |
| Q3 FY2022 | Sep 30, 2022 | $201.07M | +7.2% |
| Q2 FY2022 | Jun 30, 2022 | $225.52M | +5.7% |
| Q1 FY2022 | Mar 31, 2022 | $256.13M | +35.8% |
| Q4 FY2021 | Dec 31, 2021 | $155.87M | -28.3% |
| Q3 FY2021 | Sep 30, 2021 | $187.55M | +5.4% |
| Q2 FY2021 | Jun 30, 2021 | $213.29M | +3.2% |
| Q1 FY2021 | Mar 31, 2021 | $188.65M | -19.7% |
| Q4 FY2020 | Dec 31, 2020 | $217.43M | -17.1% |
| Q3 FY2020 | Sep 30, 2020 | $178.00M | -34.0% |
| Q2 FY2020 | Jun 30, 2020 | $206.64M | -30.1% |
| Q1 FY2020 | Mar 31, 2020 | $234.93M | +25.0% |
| Q4 FY2019 | Dec 31, 2019 | $262.39M | +22.2% |
| Q3 FY2019 | Sep 30, 2019 | $269.67M | +13.5% |
| Q2 FY2019 | Jun 30, 2019 | $295.80M | +15.8% |
| Q1 FY2019 | Mar 31, 2019 | $187.97M | +61.0% |
| Q4 FY2018 | Dec 31, 2018 | $214.74M | +65.6% |
| Q3 FY2018 | Sep 30, 2018 | $237.54M | +143.0% |
| Q2 FY2018 | Jun 30, 2018 | $255.51M | +1150.7% |
| Q1 FY2018 | Mar 31, 2018 | $116.73M | +340.5% |
| Q4 FY2017 | Dec 31, 2017 | $129.66M | +1038.2% |
| Q3 FY2017 | Sep 30, 2017 | $97.77M | – |
| Q2 FY2017 | Jun 30, 2017 | $20.43M | – |
| Q1 FY2017 | Mar 31, 2017 | $26.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.39M | – |
See a number that looks wrong?